The National Primary Health Care Development Agency (NPHCDA) said a total of 8,439 mild adverse events following immunisation (AEFI) had been reported since vaccination began in March.
Dr Faisal Shuaib, the executive director and CEO, NPHCDA, said this at a press conference by NPHCDA and World Health Organisation (WHO) on Friday in Abuja, on the status of the COVID-19 vaccination in the country.
“Out of over a million persons given the Oxford-AstraZeneca COVID-19 vaccine in Nigeria, 8,439 persons have suffered mild Adverse Events Following Immunisation (AEFI), and 52 persons moderate to severe adverse events on receiving the jab.
“While the mild reactions include body pains and swelling, the moderate to severe adverse events presented were fever, vomiting, diarrhoea headaches, dizziness and allergic reactions,” he explained.
Shuaib said there had been no death from the administration of the vaccine and no case of blood clots related to the administration of the vaccines in the country.
The ED further said five states had the highest records of the AEFI namely: Kaduna (970) Cross River (859), Yobe (541), Kebbi (511) and Lagos (448). He said these cases were being investigated to ensure they were caused by vaccination.
Shuaib restated that there was currently a global shortfall of COVID-19 vaccines, forcing the federal government to reassess vaccine supply forecasts.
He said this prompted the decision to ensure that everyone who had taken the vaccine in the current phase received the second dose before the next consignment was delivered to Nigeria.
“Furthermore, as a result of this overall programme review to meet the challenges of global vaccine demand and supply mismatch, and the late commencement of the vaccination in some states, we are expanding the eligibility period between the first and second doses of the vaccine from 12 weeks to between eight to 12 weeks.
“This is still in line with the scientific recommendation provided by the World Health Organisation’s Strategic Advisory Group of Experts (SAGE on immunisation) that the two doses of the vaccine be given at an interval of 8 to 12 weeks,” he explained. (Guardian)